Ivan Blanarik Therapeutic Area Head Respiratory
Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
Search
Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Respiratory Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care
New vaccine against Bovine Respiratory Disease
Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
Digital Therapeutic
Digital Therapeutic
Partnership-with-clicktherapeutics
Boehringer Ingelheim collaborates with Click Therapeutics on prescription-based digital therapeutic to potentially aid in the treatment of schizophrenia
Veronika Kohlbrenner
Veronika Kohlbrenner, Patient Safety Physician in Therapeutic Area Inflammation, tells us how she is able to work across different levels of the drug development process.
The digital therapeutic solution halving hospitalization rates
Around 750,000 people live with chronic heart failure in Canada. The Medly program empowers patients with heart failure to manage their condition
Ivana Ritter
Find out how Ivana become our Global Head of Safety.
Introduction to head-to-head trials
Hear from experts Dr Kerr and Dr Melosky.
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Our core product areas
Our core product areas
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Imagine: Ecological stoves safeguard family health in Mexico
With Fondo Para la Paz, we’ve developed ecological stoves for safer indoor cooking, enhancing respiratory health for rural Mexican families
CT-155
Digital therapeutic
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D portfolio
Therapeutics
Therapeutics
Respiratory Diseases
Respiratory Diseases
New Therapeutic Antibody Discovery Collaboration
Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.